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Individuals infected with SARS-CoV-2 develop neutralising antibodies. We investigated the
proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how
this proportion varies with selected covariates.
Methodology/Principal findings
This systematic review and meta-analysis examined the proportion of individuals with
SARS-CoV-2 neutralising antibodies after infection and how these proportions vary with
selected covariates. Three models using the maximum likelihood method assessed these
proportions by study group, covariates and individually extracted data (protocol
CRD42020208913). A total of 983 reports were identified and 27 were included. The pooled
(95%CI) proportion of individuals with neutralising antibodies was 85.3% (83.5–86.9) using
the titre cut off >1:20 and 83.9% (82.2–85.6), 70.2% (68.1–72.5) and 54.2% (52.0–56.5)
with titres >1:40, >1:80 and >1:160, respectively. These proportions were higher among
patients with severe COVID-19 (e.g., titres >1:80, 84.8% [80.0–89.2], >1:160, 74.4% [67.5–
79.7]) than those with mild presentation (56.7% [49.9–62.9] and 44.1% [37.3–50.6], respec-
tively) and lowest among asymptomatic infections (28.6% [17.9–39.2] and 10.0% [3.7–
20.1], respectively). IgG and neutralising antibody levels correlated poorly.
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Conclusions/Significance
85% of individuals with proven SARS-CoV-2 infection had detectable neutralising antibod-
ies. This proportion varied with disease severity, study setting, time since infection and the
method used to measure antibodies.
Author summary
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) elicits adaptive immu-
nological responses, including immunoglobulins A, M, and G and neutralising antibodies.
Neutralising antibodies are considered markers of functional immunity and protection.
However, not all individuals with proven infections have detectable neutralising antibod-
ies. In this systematic review, we investigated the proportion of individuals with former
SARS-CoV-2 infections who develop neutralising antibodies, whether their titres vary
with disease severity, and their correlation with Immunoglobulin G. We found that
approximately 85% of individuals with SARS-CoV-2 infection have detectable neutralis-
ing antibodies. This proportion was higher among patients with severe Coronavirus Dis-
ease 19 and lower in asymptomatic infections. The variation across studies reflected the
wide range of methods used to measure both immunoglobulins and neutralising antibod-
ies, and highlight the need for an international reference standard to measure SARS-CoV-
2 antibodies.
Introduction
The emergence of Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respi-
ratory Syndrome Coronavirus-2 (SARS-CoV-2), in December 2019 [1] marked the start of the
first global pandemic of this century, resulting in over 34 million cases and 1 million deaths in
the following six months [2]. SARS-CoV-2 infection has a wide spectrum of manifestations
ranging from asymptomatic infections to a multi-system disease with multi-organ involve-
ment and a high mortality [3]. Its diagnosis is based on the detection of viral RNA using
Reverse Transcription Polymerase Chain Reaction (RT-PCR) or rapid antigen tests [4].
SARS-CoV-2 specific assays to detect immunoglobulins (Ig) G, M, and A are well established
and individuals with anti-SARS-CoV-2 antibodies are expected to have some degree of protec-
tion against infection [5]. However their correlation to functional immunity is poorly
described [6].
Functional immunity is better depicted by measuring neutralising antibodies, which bind
to viral surface proteins, and prevent cell infection and plaque formation in cell cultures [7].
There is however a wide array of methodologies to measure neutralising antibodies, from
employing microscopy to measuring cell metabolism in the presence of virus and antibody. In
addition, reporting measures differ between studies, some plot a sigmoid curve and report the
viral titres that reduce viral plaques or cell metabolism to 50%, and others report the minimum
antibody titre that abolishes all viral activity in cell culture.
Here we present a systematic review and meta-analysis to describe the proportion of indi-
viduals who develop SARS-CoV-2 neutralising antibodies after infection, whether this propor-
tion varies with disease severity, the time after symptoms onset, and the correlation between
IgG and neutralising antibodies titres.
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Methods
This study followed the preferred reporting items for systematic reviews and meta-analy-
ses (PRISMA) guidelines [8]. Institutional review board approval and informed consent
were not required because all data were obtained from secondary data sources and were
de-identified. Similarly, the study used secondary sources of data and was not possible to
seek public and patient involvement. The study protocol was registered at PROSPERO
(CRD42020208913).
Search strategy and selection criteria
We conducted a systematic search of publications using the PubMed (including MEDLINE),
Web of Science, and Cochrane databases, and of preprints in bioRxiv, medRxiv and the Colla-
bovid.org website, which includes a compilation of manuscripts on COVID-19 from arXiv,
bioRxiv, Elsevier and medRxiv. The search included reports from 1st January 2020 to 12th
August 2020 and was limited to human studies. The search terms used were: “severe acute
respiratory coronavirus 2” OR “SARS-CoV-2” OR “sars AND virus” OR “sars AND cov” OR
“COVID-19” OR “COVID 2019” OR “novel coronavirus” OR “new coronavirus” OR “Wuhan
coronavirus” OR “Coronavirus disease 19” OR “2019-nCoV” AND “neutralising antibod�”
OR “neutralizing antibod�” OR “neutralising AND antibod�” OR “neutralizing AND anti-
bod�”, without language restrictions (S1 Table). Two reviewers (HRS and TE) independently
screened the titles and abstracts and selected full text manuscripts to assess for inclusion. Stud-
ies were retained if they had tested for neutralising antibodies against SARS-CoV-2 in partici-
pants with laboratory confirmed SARS-CoV-2 infection. We included studies that reported
aggregated or individual data or where data could be extracted from graphical displays. We
excluded studies without original data, if data could not be extracted, or if the titre cut offs
used were not comparable to other studies. Studies including SARS-CoV-2 vaccinated patients
or individuals receiving plasma therapy were excluded.
Data extraction and bias assessment
Data were extracted using a pre-piloted extraction form, including author, year, country, study
design, setting (hospital, community or plasma donor), age, gender, severity of symptoms
(asymptomatic, mild, moderate, severe), and weeks/months elapsed since infection. Labora-
tory data included the assay used to measure neutralising antibodies, the plaque reduction
threshold used to classify participants as having neutralising antibodies, the lower threshold
attained, additional titre thresholds used, and the IgG Enzyme linked immunoassay (ELISA)
used. Data were extracted from digitised graphs using Engauge software for individual data
extraction (http://markummitchell.github.io/engauge-digitizer/). Data were selected using a
50% plaque reduction cut off for neutralising antibody titres (i.e., 50% of the virus in the cul-
ture was neutralised by the patient’s serum (PRNT50)) or the PRNT90 for one study in which
the PRNT50 was not provided. Immunoglobulins usually increase on week after infection and
peak after 21 days. Thus, for studies that described a time window for sample collection (i.e.,
7–10 days) we recorded the end of the window to generate the most conservative estimate. We
extracted data for titre cut offs 1:20, 1:40, 1:80, and 1:160, as these were the dilutions used by
most studies.
The NIH Study Quality Assessment tool was used to assess the risk of bias and study quality
for case series and cohort studies (https://www.nhlbi.nih.gov/health-topics/study-quality-
assessment-tools). Studies were initially rated as having good, fair, or poor quality, and ratings
were discussed to reach consensus.
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Data analysis
We developed three statistical models in an R software environment to assess 1) the combined
proportion of individuals with neutralising antibodies across studies; 2) the correlation
between the proportions of participants with IgG and neutralising antibodies and 3) the corre-
lation between individual-level IgG and neutralising antibodies. The meta-analysis combined
the proportion of participants with neutralising antibodies across all studies. We used the max-
imum likelihood method with a quasi-Monte Carlo approximation. Ten thousand samples
were simulated using the inverse transformation method by conditioning on different vari-
ables that could modify the proportion positive, including disease severity, participant recruit-
ment setting, and neutralising antibody detection method. The resulting proportions were
summarised as means and 95% confidence intervals. The correlation between the proportions
of participants in a study with IgG and neutralising antibodies was estimated using a quasi-
Monte Carlo method for maximum likelihood estimation, adjusting for study setting, titre cut
off threshold, and neutralising antibody detection method. The 95% confidence intervals were
obtained via parametric bootstraps. The individual correlation model was a bivariate model of
individually extracted IgG and neutralising antibody data. Each study was modelled separately
because studies used different ELISA and reporting units and did not provide enough back-
ground to standardise results. The model was fitted using a maximum likelihood method, with
covariates taken from each study. A more detailed description of the statistical methods is
available in the supporting information (S1 Text).
Results
The search identified 983 reports. After screening titles and abstracts 78 full-text articles were
assessed for eligibility, resulting in 27 studies that met the criteria for inclusion in the analysis
(Fig 1). Twelve studies were case series and fifteen cohort studies, as shown in Table 1. Seven-
teen studies were conducted in hospital settings, three in community or outreach centres, and
seven were based on plasma donors. Thirteen studies included hospitalised and eleven conva-
lescent patients. Only one study included children. IgG was assessed using eleven in-house
and 16 commercial ELISAs. Neutralising antibodies were detected using the Focus Reduction
Neutralisation Test (FRNT) by two studies, the PRNT by five studies, the Virus Neutralisation
Test (VNT) by three studies, the surrogate VNT by one study, the pseudovirus VNT by nine
studies and the microneutralisation method by seven studies.
The risk of bias in the studies is shown in the supporting information (S2 Table). The main
risk identified was the lack of sample size estimations, as only two studies included pre-study
sample size estimations, and sample sizes were usually based on the number of cases or sam-
ples available. None of the studies reported blinding of the endpoints. Four studies were con-
sidered to have fair and 23 to have good study quality.
Proportion of participants with SARS-CoV-2 neutralising antibodies
Eighteen studies reported the proportion of participants with SARS-CoV-2 neutralising anti-
bodies with titres >1:20 [9–26], 18 reported titres >1:40 [9–12,14,16,17,19–22,25,27–32],17
reported titres >1:80 [9–12,14,16,17,19–22,25,27,29,33–35], and 18 reported titres >1:160 [9–
12,14–17,19–22,25,27,29,32–34]. The pooled proportion of participants with neutralising anti-
bodies varied with the titre threshold used (Fig 2) and ranged from 85.3% (95%CI 83.5 to 86.9)
in studies using threshold titres >1:20; 83.9% (95%CI 82.2 to 85.6) with titres >1:40, and
70.2% (95%CI 68.1 to 72.5) and 54.2% (52.0 to 56.5) with titres >1:80 and>1:160, respectively
(Table 2).
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The proportion of participants classified as having neutralising antibodies varied with the
detection method, with the pseudovirus method reporting the highest and the microneutrali-
sation method the lowest proportion of participants detectable (titre threshold >1:20, 94.9%
[95%CI 90.2 to 98.0] and 66.8% [95%CI 55.0 to 75.2], respectively), with similar differences
Fig 1. Flow diagram of study selection.
https://doi.org/10.1371/journal.pntd.0009551.g001
PLOS NEGLECTED TROPICAL DISEASES SARS-CoV-2 neutralising antibodies
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009551 July 8, 2021 5 / 17









Brochot et al France Cohort H Inpatient M/S ELISA IH S1, S2, N,
RBD
Pseudovirus VNT 30







Kohmer et al Germany Case
series





Bonelli et al Italy Cohort H Inpatient/
Community



















Zhang et al China Case
series





Stromer et al Germany Case
series














Liu et al China Case
series
H Paediatric M/S n/a n/a Pseudovirus VNT 9
Crawford et al USA Cohort H/C Convalescent A/M/Md ELISA IH1
IH2
S Psuedovirus VNT 34
















Zeng et al USA Cohort H Inpatient M/M Epitope
diagnostics
N PseudovirusVNT 55
Ko et al South
Korea
Cohort H Inpatient A PCL N, S Microneutralisation 15
Ruetalo et al Germany Case
series







Lee et al USA Cohort PD Convalescent A/Md/Md/S ELISA IH RBD PRNT 149
Wu et al China Case
series







Bosnjak et al Germany Cohort H Inpatient M Euroimmun S1 Surrogate VNT 40
Jaaskelainen et al Finland Case
series







Percivalle et al Italy Cohort PD Convalescent A/M/Md/S n/a n/a Microneutralisation 38
Suthar et al USA Case
series
H Inpatient M/Md ELISA IH RBD FRNT 44
Zettl et al Germany Cohort H Inpatient M/Md/S Euroimmun S1 VNT 25
(Continued)
PLOS NEGLECTED TROPICAL DISEASES SARS-CoV-2 neutralising antibodies
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009551 July 8, 2021 6 / 17
reported at all titre cut-offs (Table 2). The pooled proportion positive varied with disease sever-
ity (Fig 3). Studies focusing on severe COVID-19 reported higher proportions with neutralis-
ing antibodies than studies focusing on mild COVID-19, especially if they had used titre
thresholds >1:80 (84.8% [95%CI 80.0 to 89.2] and 56.7% [95%CI 49.9 to 62.9], for severe and
mild COVID-19, respectively) or>1:160 (74.4% [95%CI 67.5 to 79.7] and 44.1% [95%CI 37.3
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Fig 2. Estimated pooled proportion (95% confidence interval) of participants with neutralisation antibodies by titre cut-off
and time.
https://doi.org/10.1371/journal.pntd.0009551.g002
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Table 2. Estimated proportion of participants with neutralising antibodies with titre cut off> 1:20, 1:40, 1:80 and 1:160 by timepoints and selected covariates.
Cut off >20 Cut off >40 Cut off >80 Cut off >160
Variables % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Any time
Overall 85.3 (83.5–86.9) 83.9 (82.2–85.6) 70.2 (68.1–72.5) 54.2 (52.0–56.5)
Severity
Asymptomatic 14.4 (2.3–35.4) 97.9 (89.1–100.0) 28.6 (17.9–39.2) 10.0 (3.7–20.1)
Mild 81.2 (76.5–85.3) 79.3 (74.2–84.2) 56.7 (49.9–62.9) 44.1 (37.3–50.6)
Mixed–excluding severe 93.2 (85.1–97.9) 87.1 (76.1–94.5) 68.9 (59.6–77.9) 53.1 (40.7–64.9)
Mixed–including severe 92.8 (88.6–96.2) 76.8 (72.9–80.2) 88.0 (84.3–91.2) 62.6 (57.7–68.5)
Moderate 82.3 (70.5–90.7) 86.1 (79.5–91.1) 73.6 (62.1–82.4) 57.6 (47.1–67.4)
Severe 89.3 (83.7–93.6) 90.0 (85.0–94.0) 84.8 (80.0–89.2) 74.4 (67.5–79.7)
Unknown 76.4 (57.0–90.1) – – –
Setting
Community 63.4 (57.6–70.0) 85.7 (80.6–89.9) 53.5 (46.6–60.2) 45.5 (39.9–52.4)
Plasma donor 78.9 (75.3–82.1) 66.8 (62.5–71.4) 66.0 (61.8–70.1) 41.1 (36.8–46.3)
Hospital 93.4 (91.0–95.1) 88.9 (86.7–90.9) 75.1 (72.7–78.2) 61.9 (58.9–64.8)
Hospital/Community 93.6 (86.9–98.2) – – 65.4 (57.8–89.6)
Not stated – 98.3 (91.9–100.0) – –
Method
VNT 76.8 (72.4–80.6) 81.3 (76.1–85.7) 54.3 (49.3–58.7) 43.4 (37.8–48.7)
Surrogate VNT 96.0 (90.8–98.7) – – –
Microneutralisation 74.6 (69.5–79.1) 72.3 (68.6–75.8) 53.9 (49.4–58.3) 31.5 (27.4–35.8)
FRNT 95.1 (92.1–97.4) 95.5 (91.5–98.1) 88.4 (80.1–94.2) 79.0 (72.3–84.8)
PRNT 82.6 (77.2–87.6) 86.2 (82.8–90.3) 74.7 (69.6–82.9) 59.1 (54.2–65.5)
Pseudovirus 95.0 (91.0–97.5) 95.0 (91.6–97.3) 86.1 (82.7–89.0) 43.4 (37.8–48.5)
Month 1
Overall 86.4 (82.8–89.2) 80.9 (77.6–84.1) 68.3 (64.6–72.2) 60.7 (55.8–65.1)
Severity
Asymptomatic – – – –
Mild 77.3 (67.7–86.0) 70.7 (60.7–80.3) 54.1 (40.4–65.3) 50.3 (38.4–61.6)
Mixed–excluding severe 90.8 (77.7–98.0) 87.5 (62.2–99.4) 66.3 (35.1–90.7) 65.5 (33.9–89.3)
Mixed–including severe 93.7 (88.9–97.4) 88.0 (79.1–95.0) 72.6 (62.0–81.2) 61.6 (53.9–74.2)
Moderate 80.5 (70.7–90.2) 74.1 (65.0–83.5) 67.3 (58.2–77.2) 58.1 (50.7–66.8)
Severe 81.9 (65.6–90.2) 79.0 (69.6–87.2) 70.5 (62.1–79.1) 65.0 (46.8–74.6)
Unknown – – – –
Setting
Community 98.3 (92.9–100) 98.8 (93.4–100.0) 97.7 (90.2–100.0) 97.6 (90.1–100.0)
Plasma donor 66.9 (55.0–75.2) 53.8 (45.2–61.8) 33.9 (26.1–42.4) 39.1 (29.7–46.6)
Hospital 92.5 (89.1–95.1) 90.0 (86.0–93.3) 77.8 (72.5–82.4) 70.6 (64.2–76.3)
Hospital/Community 93.8 (87.8–97.9) – – –
Method
VNT – – 54.1 (40.2–69.4) –
Surrogate VNT – – – –
Microneutralisation 66.8 (55.0–75.2) 53.8 (45.2–61.8) 33.9 (26.1–42.4) 32.7 (20.5–41.4)
FRNT 94.0 (90.7–96.7) 93.4 (88.5–96.8) 81.0 (72.5–87.7) 68.6 (59.8–76.2)
PRNT 84.6 (75.3–92.2) 84.6 (75.1–91.9) 78.5 (68.5–87.3) 65.6 (58.3–76.7)
Pseudovirus 94.9 (90.2–98.0) 92.0 (86.0–96.5) 84.8 (77.5–90.6) 80.4 (71.6–87.7)
Month 2
(Continued)
PLOS NEGLECTED TROPICAL DISEASES SARS-CoV-2 neutralising antibodies
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009551 July 8, 2021 8 / 17
Table 2. (Continued)
Cut off >20 Cut off >40 Cut off >80 Cut off >160
Variables % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Overall 81.5 (76.3–85.6) 92.6 (88.5–95.1) 57.5 (53.4–62.7) 61.6 (57.4–65.2)
Severity
Asymptomatic – – 19.0 (4.4–41.7) 6.9 (0.3–22.5)
Mild 66.2 (53.5–78.5) 87.7 (81.1 to 93.3) 48.4 (39.1–57.9) 25.8 (18.1–34.8)
Mixed–excluding severe 97.3 (91.6–99.9) 97.9 (92.3 to 99.9) 91.8 (82.3–97.6) 75.4 (62.8–85.8)
Mixed–including severe 88.0 (70.6–95.4) 88.7 (73.0 to 94.6) 64.3 (60.3–68.1) 77.7 (71.0–83.5)
Moderate 74.0 (56.4–86.5) 92.6 (77.8 to 99.6) 85.6 (57.1–99.2) 48.9 (17.0–79.5)
Severe 75.3 (65.1–84.9) 96.7 (90.0 to 99.7) 75.4 (61.7–89.3) 77.2 (64.6–88.3)
Unknown – – – –
Setting
Community – – – –
Plasma donor 71.8 (64.1–78.8) 87.2 (77.6–93.7) 56.0 (49.2–60.8) 70.4 (61.9–77.7)
Hospital 87.3 (80.4–91.9) 91.8 (85.7–94.8) 57.9 (52.8–64.7) 58.7 (53.6–62.9)
Hospital/Community – – – –
Not stated – 98.5 (93.2–100.0) – –
Method
VNT – – 4.5 (0.6–12.1) –
Surrogate VNT – – – –
Microneutralisation 71.8 (64.1–78.8) 93.7 (88.6–96.9) 52.8 (47.3–57.9) 37.3 (30.0–44.2)
FRNT 77.3 (54.8–90.9) 94.7 (75.9–100.0) 40.0 (28.1–52.0) 80.7 (60.3–93.0)
PRNT 86.3 (78.1–92.6) 73.3 (64.2–81.7) 64.5 (59.4–69.6) 71.6 (66.4–76.8)
Pseudovirus 93.7 (90.0–96.9) 97.5 (93.8–99.3) 79.5 (70.0–95.3) 73.9 (68.9–8.3)
https://doi.org/10.1371/journal.pntd.0009551.t002
Fig 3. Estimated proportion positive (95% confidence interval) by disease severity, titre cut-off and time.
https://doi.org/10.1371/journal.pntd.0009551.g003
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of asymptomatic infections (14.4% with a titre threshold >1:20 [95%CI 2.3 to 35.4]; 97.1%
with a titre >1:40 [one study, 95%CI 89.1 to 100], 28.6% with >1:80 [95%CI 17.9 to 39.2] and
10.0% [3.7 to 20.1] with>1:160). These associations were reflected in studies recruiting
patients in hospitals, which had higher proportions of participants with neutralising antibodies
than those recruiting among plasma donors or the community (titres >1:20: 93.4% [95%CI
91.0 to 95.1] compared with 78.9% [95%CI 75.3 to 82.1] and 63.4% [95%CI 57.6 to 70.0],
respectively).
Studies reporting the proportion of patients with neutralising antibodies one and two
months after infection were analysed separately to assess the effect of time on the development
of antibias during the early stages after infection. The pooled proportion with neutralising
antibodies among plasma donors was higher in month two than in month one although this
was not statistically significant for most thresholds (Table 2). In contrast, in studies recruiting
from hospital settings, the proportion of participants with neutralising antibodies was higher
in month two at titres > 1:80 (77.8% [95%CI 72.5 to 82.4] to 57.9% [95% CI 52.8 to 64.7],
>1:160 70.6% [95%CI 64.2 to 76.3] to 58.7% [95%CI 53.6 to62.9]). The pooled prevalence one
and two months after infection had the same overall pattern, with the proportions being higher
among participants with severe than mild COVID-19 (Table 2). The proportion positive in
month two was lowest with the microneutralisation method than with the FRNT, PRNT and
pseudovirus methods at titres >1:160 (37.3% [95%CI 30.0 to 44.2]; 80.7% [95%CI 60.3 to
93.0], 71.6% [95%CI 66.4 to 76.8] and 73.9% [95%CI 68.9 to 78.3], respectively).
Correlation of neutralising and IgG antibodies
The modelled correlation between the aggregate proportion of patients with measurable IgG
against SARS-CoV-2 and neutralising antibodies was very low (0.055, corresponding to poor
correlation). The estimate was not modified by the assays, titre cut-offs used or the study set-
ting (Table 3). The correlation between individual IgG and neutralising antibodies ranged
from 0.16 to 0.756 across the studies (Table 4 and Fig 4). The correlation between individual
values was higher than the correlation of aggregated data, but there was a high variability
across studies, as shown in Fig 5. We were unable to explore whether the IgG ELISA or neu-
tralising method used modified the correlations as each study used a unique set of IgG and
Table 3. Maximum likelihood estimates (95% confidence interval) of the bivariate binomial mixed model. The estimates for the intercept, titre cut off, setting and
method are reported on the log-odds scale.
Covariate Immunoglobulin G Neutralizing antibodies
Intercept 5.398 (0.502 to 7.726) 2.903 (0.206 to 5.112)
Titre cut off 0.003 (-0.002 to 0.029) -0.003 (-0.008 to 0.003)
Setting (ref. “Community”)
Hospital -1.640 (-4.051 to 0.122) -0.298 (-1.874 to 1.305)
Not stated 18.936 (0.334 to 56.965) 1.401 (-0.957 to 4.611)
Plasma donor -1.658 (-3.996 to 0.137) -1.163 (-2.994 to 0.574)
Method for nAB (ref. “FRNT”)
Microneutralisation -0.504 (-2.220 to 1.230)
PRNT -0.782 (-2.436 to 0.757)
Pseudovirus 0.639 (-2.176 to 0.820)
VNT -0.472 (-2.256 to 1.373)
Random effects
Variance 3.762 (0.217 to 5.001)
Correlation 0.055 (4.793x10-9 to 0.500)
https://doi.org/10.1371/journal.pntd.0009551.t003
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Table 4. Maximum likelihood estimates of the correlation of IgG and neutralising antibody titres (nAB). Esti-
mates reported in a log-odds scale with 95% confidence intervals.
Study Correlation Estimate (95% Confidence intervals)
Ruetalo et al 0.727 (0.561 to 0.848)
Kohmor et al 0.589 (0.383 to 0.768)
Zettl et al 0.16 (0.01 to 0.776)
Severity (Baseline = Mixed without severe) IgG: Severe 1.094 (0.491 to 1.697)
nAB: Severe 2.363 (1.66 to 3.066)
Suthar et al 0.756 (0.589 to 0.87)
Jaaskaleinen et al 0.375 (0.155 to 0.662)
Severity (Baseline = Mild) IgG: Moderate -0.669 (-1.55 to 0.211)
IgG: Severe -0.608 (-1.545 to 0.33)
nAB: Moderate -0.897 (-1.772 to -0.022)
nABs: Severe -0.693 (-1.625 to 0.239)
Zhang et al 0.652 (0.503 to 0.776)
Severity (Baseline = Mixed without severe) IgG: Severe 0�973 (0.321 to 1.626)
nAB: Severe 1.141 (0.611 to 1.67)
Salazar et al 0.51 (0.356 to 0.661)
Severity (Baseline = Mild) IgG: Severe 1.549 (0.919 to 2.179)
nAB: Severe 1.401 (0.676 to 2.127)
Mueller et al 0.723 (0.53 to 0.858)
Severity (Baseline = Asymptomatic) IgG: Mild 1.023 (0.275 to 1.771)
nAB: Mild 2.543 (1.232 to 3.853)
Wang et al 0.597 (0.431 to 0.743)
Severity (Baseline = Mild) IgG: Severe 0.564 (0.12 to 1.008)
nAB: Severe 1.067 (0.614 to 1.521)
IgG: immunoglobulin G. nABs: neutralising antibodies.
https://doi.org/10.1371/journal.pntd.0009551.t004
Fig 4. Estimated correlation (95% confidence interval) of individual IgG and neutralising antibodies by study.
https://doi.org/10.1371/journal.pntd.0009551.g004
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neutralisation methods. In five of six studies reporting disease severity [9–11,19,21,25], there
was an increased correlation between IgG and neutralising antibodies with increasing disease
severity [10,11,19,21,25].
Discussion
Despite major efforts to understand the mechanisms for immunity after COVID-19, this is the
first comprehensive systematic review synthesising the proportion of individuals who exhibit
neutralising antibodies after natural SARS-CoV-2 infection. Although 85% of participants
with previous SARS-CoV-2 infection had detectable neutralising antibodies, there was a wide
variation across studies, which was partly explained by the method and cut off titres used.
Studies using the microneutralisation and the pseudovirus methods reported the lowest and
highest proportion of participants with neutralising antibodies, respectively, while studies
using low titre cut offs (i.e., >1:20 and>1:40) reported a higher proportion of participants as
having neutralising antibodies than those using higher titre cut offs (i.e., >1:80 and>1:160).
The proportion of participants with neutralising antibodies varied with study setting,
COVID-19 severity, and time since infection. Studies on severe COVID-19 reported higher
proportions of patients with neutralising antibodies than studies focusing on mild and moder-
ate COVID-19, with studies on asymptomatic infections having the lowest proportion of
patients with antibodies. Similarly, hospital-based studies reported higher proportions of
Fig 5. Scatterplot of individual neutralising and IgG antibody values by study.
https://doi.org/10.1371/journal.pntd.0009551.g005
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participants with neutralising antibodies than studies based in the community or plasma
donors, suggesting the study setting is a surrogate marker for disease severity. The lack of neu-
tralising antibodies in a small but significant group of patients seen in this review might be
explained by some patients having responses confined to SARS-CoV-2 antigens not identified
by the assays used, or mediated through T cells, which are not detected by the neutralisation
assays in this meta-analysis. Mild infections may also elicit responses that are restricted to the
mucosal cells, where defence responses are dominated by the secretory immune system [36].
Only a subset of studies reported the pooled proportion of neutralising antibodies one and
two months after infection. The proportion of participants with neutralising antibodies in the
second month was slightly higher among plasma donors and slightly lower among patients
recruited from hospital. However, the differences were small and confidence intervals over-
lapped. As neutralising antibodies peak within 21 days after symptoms onset, and symptoms
onset if often poorly documented, it may be that the one-month timepoint is not ideal to dem-
onstrate differences over time [37].
Surprisingly, the correlation between the detection of IgG and neutralising antibodies at
study level was low, with a better correlation for the subset of studies with individual data. This
is not surprising, as the correlation of aggregate data is necessarily a less sensitive analysis than
individual data that can show higher definition. The correlation of individual IgG levels
increased with disease severity, reaching an r value of 0.756, but with a high variation between
studies. This lack of consistency can be attributed to the neutralisation and ELISA assays used.
Neutralisation assay sensitivity varies across the methods and ELISAs are based on different
SARS-CoV-2 antigens (e.g. nucleoprotein or spike protein domains), which affect performance
[38].
Despite neutralising antibodies not being detectable in a significant proportion of partici-
pants, these antibodies are only a visible fraction of the defence mechanism against COVID-19
and second infections are rare and adaptive immunity mechanisms involving B and T cells
and mucosal neutralising antibodies are at play [39]. For example, memory B cells display
clonal turnover after six months, with maturation of response and expressed antibodies having
greater somatic hypermutation, increased potency, and resistance to the Spike protein recep-
tor-binding domain mutations, indicative of a continued evolution of the humoral response
[39].
We have examined variations resulting from study settings, testing methodologies, and dis-
ease severity and provide an overview based on a large number of studies, resourcing to indi-
vidual data whenever possible. We have shown that current information is based on a
multitude of methods assessing neutralising antibodies, a large variety of ELISAs, including
in-house methods without WHO endorsement, and that these differences lead to different
proportions of individuals being classified as having positive responses and, possibly, the poor
correlation between IgG and neutralising antibodies in aggregated datasets. These limitations
highlight the need for standardisation of the methodology and the development of guidelines
for future studies. There is a similar a lack of standardisation of objective markers on the
assessment of disease severity (e.g., C Reactive Protein) and results are often presented without
stratification, which made it difficult to perform meta-regression of subgroups. Moreover,
data on circulating SARS-CoV-2 variants, patients’ age, outcome, T cell responses, ELISA’s
spike glycoprotein targets, and other potential covariates were not available in significant num-
bers and there were no studies from South America, the Indian subcontinent, or Africa, and
results cannot be generalised to these populations.
In the event of a new pandemic virus there is a limited window where the natural epidemi-
ology of the virus can be observed prior to treatment or vaccination. Without large cohort
studies only, a fragmented picture was available, and ongoing cohorts will need to account for
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virus variants, treatment and vaccination. Combining studies and performing a meta-analysis
allowed an analysis of data from early stages and gives a more complete picture of the natural
immunity at the beginning of the pandemic.
In conclusion, a high proportion of individuals have evidence of neutralising antibodies
after SARS-CoV-2 infection. These proportions vary with disease severity, with asymptomatic
infections being less likely to have detectable antibodies than those experiencing severe
COVID-19. Most diagnostic tests, therapeutics, and vaccines are aimed at the SARS-CoV-2
Spike, and virus evasion occur through mutations that escape neutralising antibodies. Thus,
research is needed to establish whether the lack of detectable neutralising antibodies interre-
lates with virus escapees with or without a vaccine [40]. This is particularly relevant in light of
the recent dominance in parts of the UK of a strain with mutations in the spike protein that is
associated with increased transmissibility [41]. Moreover, the minimum level of neutralising
antibodies required to achieve protection is unknown at this stage, and immunological mem-
ory mechanisms may rapidly boost generation of antibodies that are not detectable in the
peripheral blood in the absence of stimulation. This review also highlights the need for guid-
ance on standardised protocols for the measurement of neutralising antibodies; for longitudi-
nal studies to document how neutralising antibodies and their relationship with IgG levels
change over time, and whether minimal or undetectable levels indicate lack of clinical protec-
tion and thus vulnerability to infection.
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20. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-throughput
SARS-CoV-2 IgG antibody assays. J Clin Virol. Elsevier; 2020; 129: 104480. https://doi.org/10.1016/j.
jcv.2020.104480 PMID: 32505777
21. Müller L, Ostermann PN, Walker A, Wienemann T, Mertens A. Sensitivity of commercial Anti-SARS-
CoV-2 serological assays in a high- prevalence setting Keywords Social and working network contacts
of the index patient SARS-CoV-2 neutralising antibody levels. 2020;
22. Ruetalo N, Businger R, Althaus K, Fink S, Ruoff F, Hamprecht K, et al. Neutralizing antibody response
in non-hospitalized SARS-CoV-2 patients. medRxiv. 2020; https://doi.org/10.1101/2020.08.07.
20169961
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